Image Credit : Unsplash
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical business.
The Company is concentrated on the advancement of GP2, immunotherapy to prevent breast cancer reoccurrences in clients who have actually formerly gone through surgical treatment.
GP2 is a 9 amino acid transmembrane peptide of the human skin development element receptor 2 (HER2)/ neu protein, a cell surface area receptor protein that is revealed in a range of typical cancers.
GP2 will be provided in mix with granulocyte-macrophage colony-stimulating aspect (GM-CSF) to cause GP2 peptide-specific resistance.
Greenwich Lifesciences Inc stock price is 13.95 USD
The 1 experts providing 12-month cost projections for Greenwich Lifesciences Inc have a typical target of 78.00, with a high price quote of 78.00 and a low price quote of 78.00.
The mean price quote represents a +469.14% boost from the last rate of 13.71.